Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice

Ilie-Cosmin Stancu1 · Bruno Vasconcelos1 · Laurence Ris² · Peng Wang1 · Agnès Villers2 · Eve Peeraer3 · Arjan Buist1 · Dick Terwel4 · Peter Baatsen5 · Tutu Oyelami3 · Nathalie Pierrot1 · Cindy Casteels6 · Guy Bormans6 · Pascal Kienlen-Campard1 · Jean-Nöel Octave1 · Diederik Moechars3 · Ilse Dewachter1

Received: 29 September 2014 / Revised: 11 March 2015 / Accepted: 12 March 2015 / Published online: 11 April 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract Prion-like seeding and propagation of Tau-pathology have been demonstrated experimentally and may underlie the stereotyped progression of neurodegenerative Tauopathies. However, the involvement of templated misfolding of Tau in neuronal network dysfunction and behavioral outcomes remains to be explored in detail. Here we analyzed the repercussions of prion-like spreading of Tau-pathology via neuronal connections on neuronal network function in TauP301S transgenic mice. Spontaneous and GABA<A>,-R-antagonist-induced neuronal network activity were affected following templated Tau-misfolding using synthetic preformed Tau fibrils in cultured primary neurons. Electrophysiological analysis in organotypic hippocampal slices of Tau transgenic mice demonstrated impaired synaptic transmission and impaired long-term potentiation following Tau-seed induced Tau-aggregation. Intracerebral injection of Tau-seeds in TauP301S mice, caused prion-like spreading of Tau-pathology through functionally connected neuroanatomical pathways. Electrophysiological analysis revealed impaired synaptic plasticity in hippocampal CA1 region 6 months after Tau-seeding in entorhinal cortex (EC). Furthermore, templated Tau aggregation impaired cognitive function, measured in the object recognition test 6 months post-seeding. In contrast, Tau-seeding in basal ganglia and subsequent spreading through functionally connected neuronal networks involved in motor control, resulted in motoric deficits reflected in claspng and impaired inverted grid hanging, not significantly affected following Tau-seeding in EC. Immunostaining, biochemical and electron microscopic analysis in the different models suggested early pathological forms of Tau, including Tau-oligomers, rather than fully mature neurofibrillary tangles (NFTs) as culprits of neuronal dysfunction. We here demonstrate for the first time using in vitro, ex vivo and in vivo models, that prion-like spreading of Tau-misfolding by Tau seeds, along unique neuronal connections, causes neuronal network dysfunction and associated behavioral dysfunction. Our data highlight the potential relevance of this mechanism in the symptomatic progression in Tauopathies. We furthermore demonstrate that the initial site of Tau-seeding thereby determines the behavioral outcome, potentially underlying the observed heterogeneity in (familial) Tauopathies, including in TauP301 mutants.

Keywords AD · Tauopathies · Tau · Prion-like propagation · Tau-pathology · Neuronal network · Synaptic · Cognition · Motoric deficits · TauP301 heterogeneity
Introduction

Tauopathies are a diverse group of neurodegenerative diseases, characterized by the presence of Tau aggregates composed of misfolded hyperphosphorylated Tau [7, 41, 62]. In Tauopathies, symptoms correlate strongly with the regional distribution of Tau-aggregates in the brain. In Alzheimer’s Disease, the most common Tauopathy, Tau aggregate formation progresses in a stereotypic pattern, along functionally connected neuroanatomical pathways, used for staging disease progression [2, 6, 34, 59]. In AD, Tau pathology starts in the entorhinal cortex (EC), progresses to the limbic regions such as subiculum, hippocampal cornu ammonis (CA) and amygdala (stages III and IV), and finally involves neocortical areas (stages V and IV), according to the Braak and Braak stages [6, 59]. Defects in neuronal function and neuronal loss of the affected or connected neurons are believed to contribute to the disease symptoms by affecting functionally critical neuronal networks, while the mechanism remains poorly understood [6, 15, 24, 58, 74].

Accumulating evidence indicates that Tau and related proteins linked to neurodegenerative proteinopathies display prion-like properties [12–14, 19, 22, 25, 26, 28, 32, 35, 37, 72]. In vitro studies have demonstrated that extracellular misfolded Tau can be taken up by cultured cells, can seed aggregation of endogenous soluble Tau and can propagate a fibrillar, misfolded state between co-cultured cells [20, 26, 32, 53]. Injections of brain lysates from neurofibrillary tangle (NFT) bearing transgenic mice into wild type Tau-expressing transgenic mice that do not develop NFTs, induce Tau pathology that spreads to brain regions remote from the injection site by connectivity rather than proximity [1, 13]. This has been recapitulated with brain extracts from patients with different Tauopathies, mimicking distinct forms of Tau-aggregation—in a cell-type and region specific way—reminiscent for the respective Tauopathies [5, 12]. Injection of pre-aggregated synthetic full length Tau and Tau fragments results in seeding and spreading of Tau-pathology in cells and in Tau transgenic mice, demonstrating that misfolded Tau per se, and not a different factor in the brain extracts, is sufficient to induce Tau-aggregation [35]. Induction of Tau-aggregation by misfolded Tau has been demonstrated in non-transgenic mice [40], albeit at later age and to a more limited extent. Indefinite and stable maintenance of unique conformations—“strains”—in vivo that link structure to patterns of pathology was recently demonstrated, further corroborating prion-like properties of misfolded Tau [5, 53]. Although increasing dysfunction in neuronal networks is believed to explain the progression of behavioral disease symptoms, including memory loss [22, 28, 53, 58, 59], it remains to be demonstrated whether this can be caused by prion-like spreading of Tau-pathology. This is not a trivial question, as previous reports have indicated that NFTs per se may not disturb neuronal function and could be an off-pathway disease side effect [30, 38, 48, 52, 54, 61, 65, 66, 69].

In this work, we have addressed this question using in vitro, ex vivo and in vivo models with induction and spreading of Tau-pathology. Seeding of Tau pathology was shown to impair neuronal network function in primary neuronal cultures and in organotypic hippocampal slices. Furthermore, Tau-seeding caused prion-like spreading of Tau-aggregation through functionally connected neuronal networks and neuronal network dysfunction in TauP301S transgenic mice, leading to either cognitive or motoric deficits, depending on the initial site of Tau-seeding. Our data furthermore point to early pathological forms of Tau, including Tau oligomers, rather than somatic NFTs as culprits for the functional deficits.

Materials and methods

Animals

Transgenic TauP301S mice (PS19) [73] expressing human Tau-P301S (1N4R), driven by the mouse prion protein promoter were backcrossed to C57B6 and used in this study. TauP301S mice bred and used in our lab, develop a neurodegenerative phenotype similar as previously reported, at ~10–11 months [35, 63, 73]. Stereotactic injections were performed at 3 months and age-matched littersmates were used for analysis at different time points post-injection. All experiments were performed in compliance with protocols approved by the UCLouvain Ethical Committee for Animal Welfare.

Tau aggregation assays

Generation of Tau-PFFs from recombinant Tau

Tau-PFFs (synthetic preformed fibrils) or Tau-seeds were generated as described [26, 35]. Briefly, truncated human Tau fragments (WT-Tau/P301L-Tau) containing the four repeat domain [K18; Q244-E372 (4RTau)], N-terminally Myc-tagged were produced in Escherichia coli. Tau-PFFs were obtained by incubation of Tau fragments (66 μM) at 37 °C for 5 days in the presence of heparin (132 μM) in 100 mM ammonium acetate buffer (pH 7.0). Following centrifugation (100,000 x g for 1 h, 4 °C), the pellet was resuspended in the same buffer (333 μM final) and sonicated before use. Tau fibrilization was confirmed using ThioT assay (Sigma-Aldrich, St. Louis, MO, USA) and immunoblotting. In vitro Tau aggregation assay in HEK293 cells PFFs induced Tau-aggregation in vitro was essentially performed as previously [26]. Sonicated Tau-seeds (10 μM) were added to
Bio-PORTEr single use tubes (AMS Biotechnology, Milton, UK) and added to optiMEM-washed transiently transfected HEK293 (QBI) cells, 24 h post-transfection with Tau (P301L or WT). In vitro Tau-aggregation assay in primary neurons Primary cortical neuronal cultures (PNC) were generated as described previously [55], from P0 heterozygous TauP301S pups or non-transgenic (WT) littermates. Tau-seeds (10 nM) were added at DIV3 and DIV6, and primary neurons were used for calcium imaging at DIV13 and subsequently extracted or fixed for further analysis. Ex-vivo Tau-aggregation assay in organotypic hippocampal slices Organotypic hippocampal slices (OC) were generated using previously described protocols [21, 64]. Briefly, hippocampal slices were generated at P6 from heterozygous TauP301S mice and non-transgenic littermates. Tau-seeds (1 µL; 333 µM) were gently added on top of hippocampal slices at DIV3 and DIV6, and slices were analyzed electrophysiologically, biochemically and immunohistologically 10 days after seeding. Tau-seeded Tau-aggregation in vivo Sonicated pre-aggregated Tau-PFFs (5 µL; 333 µM) or vehicle without seeds (5 µL) were injected in 3 months old mice. Stereotactic injections were performed in the hippocampal CA1 region (A/P, −2.0; L, +1.4; D/V, −1.2), frontal cortex (A/P, +2.0; L, +1.4; D/V, −1.0), in entorhinal cortex (A/P, −4.8; L, −3.0; D/V, −3.7) and substantia nigra (A/P, −4.8; P/A, angle 16°; L, −1.1; D/V, −4.7) millimeter relative to bregma [45], using a 10 µL Hamilton syringe at a speed of 1 µL per min.

Biochemical analysis

For immunoblotting analysis brain regions were dissected and snap-frozen in liquid nitrogen, and subsequently differential extraction of total homogenates, sarkosyl soluble and sarkosyl insoluble fractions was performed as previously described [67, 68] and in supplemental data. Similar extraction procedures were used for primary neurons and organotypic cultures as described in supplemental data. Proteins were quantified using BCA Protein Assay kit (Thermo Fisher Scientific, Waltham, MA, USA). For dot blotting equal amounts of total homogenates were spotted on a nitrocellulose membrane and subsequently immunoblotted using T22 [ABN454 Anti-Tau (T22) oligomeric antibody; EMD Millipore], against oligomeric Tau [39]. Analysis under non-denaturing and non-reducing conditions was performed on 4-16 % Bis-Tris Native Page. For immunoblotting equal amounts of proteins were loaded on precasted gels [4–12 % (MOPS), 8 % Tris–glycine gel (Invitrogen, Life Technologies, Carlsbad, CA, USA)]. Immunoblotting was performed with anti-Tau P-S202/T205 (AT8; Thermo Fisher Scientific, Waltham, MA, USA), with anti-Tau P-S396/S404 antibody (AD2; Bio-Rad Laboratories Inc., Hercules, CA, USA), or with anti-total Tau antibody (HT7; Thermo Fisher Scientific, Waltham, MA, USA) and developed using ECL kit (PerkinElmer, Waltham, MA, USA).

Immunohistological and immunocytological analysis

Immunohistological analysis was performed as described previously [16, 17, 36, 49, 63]. Following transcardial flushing (2 min), brains were dissected and immersion fixed in 4 % paraformaldehyde in PBS for 24 h at 4 °C. Sagittal sections (40 µm) were cut on a vibrating HM650V microtome (Thermo Fisher Scientific, Waltham, MA, USA). Immunohistochemistry (IHC) with anti-Tau P-S202/T205 (AT8), anti-Tau P-S212/T214 (AT100) and anti-conformational specific Tau (MC1, Peter Davies) was done on 40 µm sagittal vibratome sections using appropriate Alexa coupled secondary antibodies (Invitrogen, Life Technologies, Carlsbad, CA, USA). Staining with Thioflavin S (ThioS; Sigma-Aldrich, St. Louis, MO, USA) and Gallyas silver staining were performed as previously described [63]. Image acquisition was performed using a digital inverted fluorescence microscope EVOS-x1 microscope (Life Technologies, Carlsbad, CA, USA), using a 4×, 10×, 20× or 40× lens, and standard light microscope. Image analysis was done using Image J (National Institutes of Health). Heat maps were generated using the HeatMap Histogram plugin for Image J. Briefly, the overview images of AT8 staining of a well-identified section of different mice (n ≥ 3 per group) were grouped. Stacked images representing averaged intensities were generated using the Image J stacking tool with the average intensities outcome option. Finally, a Gaussian Blur filter of 5.0 was applied. Immunocytochemistry (ICC) and IHC on HEK293 cells, primary neurons and organotypic cultures were performed similarly. Fixation was performed standard or under stringent extraction of soluble Tau (supplemental material). All other chemicals were from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, USA).

Neuronal network activity-synchronized cytosolic calcium oscillations

Primary neurons from P0, TauP301S mice and non-transgenic littermates were used for calcium imaging, using incubation with fura-2 acetoxy-methyl ester (Fura-2 AM; Calbiochem, Camarillo, CA, USA) 2 µM (final) in Krebs-HEPES buffer (10 mM HEPES, 135 mM NaCl, 6 mM KCl, 2 mM CaCl2, 1.2 mM MgCl2, 10 mM glucose, pH 7.4) for 30 min at RT. Coverslips were then washed in Krebs–HEPES buffer and mounted in a heated (37 °C) microscope chamber with 600 µL of buffer [44, 55]. After recording of basal spontaneous calcium oscillations, picrotoxin (PTX; Sigma-Aldrich, St. Louis, MO, USA) was added to the neurons to a final concentration of 100 µM for 3 min. Cells
were alternately excited (1 or 2 Hz) at 340 and 380 nm for 100 ms using a Lambda DG-4 Ultra High Speed Wavelength Switcher (Sutter Instrument, Novato, CA, USA) coupled to a Zeiss Axiovert 200 M inverted microscope (20x fluorescence objective) (Carl Zeiss AG, Oberkochen, DE). Images were acquired with a Zeiss Axiocam camera coupled to a 510 nm emission filter and analyzed with the AxioVision software. Calcium concentration was evaluated from the ratio of fluorescence emission intensities excited at the two wavelengths, i.e. the ratio of $F_{340}/F_{380}$. Changes in the intracellular calcium fluorescence were expressed as $\Delta F/F_0$ to represent the changes in the cytosolic calcium concentrations, relative to the resting fluorescence value $F_0$. Calcium oscillations were defined as variations of more than 10 % from $F_0$, occurring synchronously in several cells of the field.

**Functional analysis**

**Electrophysiology** Electrophysiological analysis in organotypic hippocampal slices was performed on non-seeded (vehicle) or Tau-seeded cultured hippocampal slices (at DIV3 and DIV6) from WT or TauP301S P6 pups and analyzed after the indicated time post-seeding (2, 4, 10 days). Cultures were directly placed into the recording chamber and slices were kept in interface at 28 °C for 30 min before recordings. Electrophysiological analysis in acute hippocampal slices derived from seeded and non-seeded mice was performed essentially as described previously [17, 63]. Briefly, hippocampus was dissected and cut in 450 µm-thick slices with a tissue chopper. The slices were transferred into the recording chamber and kept in interface at 28 °C for 90 min. Electrophysiological recordings Hippocampal slices were perfused with artificial cerebrospinal fluid (ACSF) with the following composition: 124 mM NaCl, 5 mM KCl, 26 mM NaHCO3, 1.24 mM NaH2PO4, 2.5 mM CaCl2, 1.3 mM MgSO4, 10 mM glucose, bubbled with a mixture of 95 % O2 and 5 % CO2. The perfusion rate of ACSF was 1 mL/min. A bipolar twisted nickel-chrome electrode (50 µm diameter) was used to stimulate Schaffer’s collaterals. Extracellular field excitatory postsynaptic potentials (fEPSP) for acute slices or population spikes (PS) for organotypic slices were recorded in the stratum radiatum of the CA1 region with low resistance (2–5 MΩ) glass microelectrodes filled with ACSF. The slope of the fEPSP or the amplitude of PS was measured on the average of four consecutive responses. LTP was induced by applying one train of high-frequency stimulation (100 Hz, 1 s). Stimulation, data acquisition and analysis were performed using the WinLTP program 28 (website: [http://www.winltp.com](http://www.winltp.com)). For each slice, the fEPSP slopes or PS amplitudes were normalized with respect to the mean slope of the fEPSPs or the mean amplitude of the PS recorded during the 30 min period preceding induction of LTP. Statistical analysis of the data was performed using one-way ANOVA or Student’s $t$ test in SigmaPlot 12.0 software (Systat Software Inc, Chicago, IL, USA). Data were expressed as mean ± SEM, and differences with $p < 0.05$...
were considered significant. **FDG-PET analysis** Brain glucose metabolism was assessed using $^{18}$F]FDG (FDG) as described in detail in supplemental data [9].

**Behavioral testing**

**The object recognition task** The object recognition task was essentially performed as previously described [17, 51]. Briefly, following 10 min habituation to the open field box ($60 \times 60 \times 50$ cm), the mice were submitted the next day to a 10 min acquisition trial. During this trial, mice were placed in the open field in the presence of object A, and the time spent exploring object A was measured. During a 10 min retention trial performed 1 h later, a novel object B was added to the arena. The recognition index (RI), defined as the ratio of the time spent exploring the novel object B over the time spent exploring both objects ($tB / (tA + tB)$) was used to measure nonspatial memory [17].

**Clasping scoring** Scoring of clasping was performed using a scale between 5 and 1, with clasping score 5 representing no clasping (normal), score 4 representing initial signs of clasping, score 3 for intermediate clasping, score 2 for strong clasping, and score 1 representing very severe (maximal) clasping. Scores between 1 and 5 were assigned by an experimentator blinded for the experimental group.

**Inverted grid hanging task** The inverted grid hanging test was used to assess the ability to grasp an elevated horizontal grid and to remain suspended for 2 min. The grid (40 cm $\times$ 20 cm/0.5 cm meshes) was positioned 50 cm above a flat, soft surface and the latency for the animal to drop off was measured.

**Immunogold electron microscopy**

Protein extracts from mouse brains, PNC, OC and HEK293 cells were applied on 300-mesh carbon-coated grids in drops of 3 µL for 5 min, blotted on a filter paper and air-dried before the immunogold procedure. Grids were blocked in PBS, 0.1 % cold water fish gelatin (PBS-CWFG) for 5 min before incubating with PBS-CWFG diluted primary antibodies (HT7 1:50, AT8 1:50, AT100 1:50) for 90 min at RT. After washing 5 times (2 min) in PBS-CWFG, grids were incubated for 60 min with secondary antibody (goat anti-mouse IgG) labeled with 10-nm gold particles (Aurion) diluted 1:30 in PBS-CWFG. Following washes in PBS and dH$_2$O, grids were negatively stained with 2 % uranyl acetate for 1 min. The grids were examined with a JEOL JEM1400 transmission electron microscopy equipped with a Olympus SIS Quemesa 11 Mpxl camera, and images were taken at magnifications of 20$\times$ and 30$\times$ k (resp. pixel size = 0.72 and 0.48 nm). Immuno-gold electron-microscopy on brain slices is described in detail in supplemental data.
Statistical analysis

Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA) using one-way analysis of variance (ANOVA) followed by Dunnett’s post hoc test and Student’s t test. Data were expressed as mean ± SEM and differences were considered significant when p values <0.05.

Results

Synthetic Tau-fibrils induce Tau-aggregation and altered neuronal network activity in primary neuronal cultures

Tau seeds extracted from brains of Tau transgenic mice with Tau pathology, from patients with different forms of Tauopathies or pre-aggregated synthetic Tau and Tau-fragments [12, 13, 35] induce Tau-aggregation in cultured cells and in vivo [19, 22, 26, 28, 53]. In this work, we used synthetic pre-aggregated Tau fragments, encompassing the four repeat domain of TauP301L, further referred to as “Tau-seeds”, to analyze the functional repercussions of Tau-aggregation in different in vitro, ex vivo and in vivo models. We first acquired and characterized Tau-seed induced Tau-aggregation in HEK293 cells, by administration of Tau-seeds to transfected TauP301L HEK293 cells using BioPORTER as previously shown [26]. Biochemical analysis demonstrated the presence of detergent insoluble (Triton-insoluble (TX-100) and sarkosyl insoluble) Tau-aggregates phosphorylated at S202/T205 (AT8) (Fig. S1a) following Tau-seeding while absent in non-seeded cells. Tau aggregation was further confirmed by immunocytochemical (ICC) analysis using a stringent extraction protocol with TX-100, extracting soluble forms of Tau from the cells, while only aggregated forms of Tau remained detectable. Staining with anti-Tau P-S202/T205 antibody (AT8) demonstrated intense staining of Tau aggregates in seeded cells, absent in non-seeded cells (Fig. S1a). Since the AT8 epitope is situated outside of the Tau-seeding fragment, this demonstrates aggregation of full length Tau and not accumulation of Tau-seeds in the cells. To determine optimal conditions for Tau-aggregation, we used different combinations of wild type Tau and mutant TauP301L forms as inducer and receiver. Immunocytological and alpha-LISA analysis demonstrated that wild type Tau was markedly less prone to aggregate than TauP301L (recipient), when seeded with either wild type or P301 mutated pre-aggregated Tau-seeds (inducer) (Fig. S1b). Similarly, wild-type Tau seeds (inducer) were less efficient compared to mutated TauP301L seeds, in inducing Tau-aggregation (Fig. S1b, c). Hence, in this work, we analyzed the functional repercussions of Tau-aggregation in optimal conditions, using Tau mutated at Proline 301 acting both as inducer and recipient.

To analyze the effect of Tau-seed induced Tau-aggregation on neuronal network function, we performed Tau-seeding in primary neurons derived from TauP301S transgenic mice [27, 63, 73]. Addition of Tau-seeds—without BioPORTER—induced Tau-aggregation in primary Tau-expressing neurons 10 days post-seeding. Tau-aggregation was demonstrated using AT8 staining following stringent extraction, demonstrating strong somatic AT8 staining in Tau-expressing cultures following Tau-seeding. No AT8 positive neurons were detected in non-seeded Tau-expressing neurons or seeded and non-seeded wild type neurons (Fig. 1a, Fig. S2). To assess if Tau-seeded Tau-aggregation affected neuronal network activity, we measured synchronized calcium oscillations using Fura-2 AM

Fig. 3 In vivo aggregation of Tau following injection of Tau-seeds. a Tau-seeding induced Tau-aggregation in vivo. I Intracerebral injection of Tau-seeds in frontal cortex and hippocampus (not shown) at 3 months in TauP301S transgenic mice induced robust Tau-pathology 6 months post-injection, in contrast to buffer only injected TauP301S mice or non-injected TauP301S mice (not shown). Representative AT8 stainings are shown (magnification ×4, ×10, ×20). Staining with AT100, Gallyas silver and ThioS are presented (magnification ×20) (scale bar ×4—1000 µm, ×10—400 µm, ×20—200 µm). II Biochemical analysis revealing Tau-seed induced Tau-aggregation, as demonstrated by immunoblotting of sarkosyl soluble and sarkosyl insoluble fractions of brain extracts. Total levels of sarkosyl soluble Tau were not significantly affected following Tau seeding, but show increased ratio of higher MW to lower MW Tau forms. Marked increase in sarkosyl insoluble Tau following Tau-seeding as revealed by immunoblotting with HT7 (total Tau) antibody, AT8 (P-S202/ T205) antibody and with AT270 (P-T181) antibody of sarkosyl insoluble fractions extracted from brains of Tau-seeded mice, 6 months post-injection, compared to non-seeded Tau mice. Sarkosyl insoluble Tau displayed a characteristic shift in mobility compared to sarkosyl insoluble Tau (arrows indicate 68 kDa). b Progressive spreading of Tau-pathology. Longitudinal analysis at different post-injection (p.i.) times (1.5 mo, 2.5 mo, 3.5 mo and 6 mo post-injection). Tau-pathology revealed by AT8 staining spreads progressively from entorhinal cortex (EC) to functionally connected hippocampal regions (CA1, CA3, DG, Sub) and amygdala (AA). At 1.5 mo p.i. NFTs are mainly restricted to EC. Note that weak axonal staining (indicated with asterisk) of mossy fibers and in DG (at 1.5 mo p.i.), does not represent NFTs but axonal staining observed in young TauP301S mice [73]. I Tau-pathology progressively spreads to the contralateral hemisphere. Medial and lateral sagittal sections (cfr Fig. 4a for schematic presentation) of the contralateral hemisphere at different times p.i. are presented (II, IV), demonstrating spreading of Tau-pathology to distant brain regions along neuronal connections (scale bar overviews—2000 µm, ×4—1000 µm). III Biochemical analysis of spreading of Tau-pathology to ipsilateral frontal cortex. Western blotting of total homogenate (frontal cortex) revealed a characteristic mobility shift (AT8 antibody) and sarkosyl insoluble Tau in frontal cortex extracts following Tau seeding in EC while absent in non-seeded Tau mice (AD-2 antibody). Quantitative analysis revealed significant increased ratio of sarkosyl insoluble to sarkosyl soluble Tau in frontal cortex following Tau-seeding in EC (n = 3 per condition; mean ± SEM are presented; *p < 0.05)
dye [44, 55]. Spontaneous calcium oscillations were rather limited in primary wild-type neurons, while amplitudes increased in TauP301S expressing primary neurons, and were significantly more pronounced and well-synchronized in Tau-seeded TauP301S expressing neurons [control (5.50 ± 0.67); Tau-neurons (10.49 ± 0.39); Tau-seeded
Tau-neurons (17.89 ± 0.78) [Fig. 1b]. Addition of picrotoxin (PTX)—a non-competitive GABA\(_A\)R-antagonist—known to induce seizures similar as PTZ—in wild-type neurons, increased robustly the amplitude of the oscillations [no PTX (5.50 ± 0.67), with PTX (64.59 ± 3.24)], increased the number of synchronously oscillating neurons and induced regularly shaped responses (characterized by a steep rise and slower decay), as reported previously [44] [Fig. 1b]. Of note, similar but less pronounced changes as PTX application are observed when comparing Tau-seeded with non-seeded Tau-expressing and wild-type neurons in unstimulated conditions. This suggests that Tau-seed induced Tau-aggregation acts similar as a GABA\(_A\)R-antagonist, resulting in impaired GABA-ergic transmission. We further identified PTX-induced calcium oscillations as excitatory AMPA- and NMDA-dependent oscillations as they were completely blocked following application of CNQX and D-APV [Fig. S2b], as shown previously [44]. Intriguingly, amplitudes of PTX-induced calcium oscillations were significantly lower in Tau-seeded Tau-expressing neurons (45.53 ± 2.18) compared to non-seeded Tau-expressing (54.51 ± 3.25) or to wild-type neurons (64.59 ± 3.24), indicating that also excitatory transmission was impaired following Tau-seeding [Fig. 1b]. Importantly, Tau-seeding in WT—non-transgenic—neurons did not induce Tau-aggregation as analyzed by AT8 staining, and did not affect spontaneous nor PTX-induced calcium oscillations [Fig. S2a, b]. Taken together, analysis of spontaneous and PTX-induced neuronal network activity, demonstrated significantly different responses in control, Tau-expressing and Tau-seeded Tau-expressing neurons, suggesting impaired GABA-ergic and excitatory synaptic transmission following Tau-seeding. Hence, Tau-seeding affects neuronal and neuronal network function. It must be noted that only 5—10 % of Tau-seeded neurons displayed strong somatic AT8 staining. Thus, either a few neurons can have a robust impact on neuronal network activity, or alternatively and most parsimoniously, other pathological forms of Tau contribute to impaired neuronal network function.

**Synthetic Tau seed induced Tau-aggregation impaired basal synaptic transmission and synaptic plasticity in organotypic hippocampal slices**

We next extended our assay ex vivo, in organotypic hippocampal cultures derived from 6 days old Tau P301S transgenic pups [64, 73]. Consecutive addition of Tau-seeds at DIV3 and DIV6 induced robust Tau-aggregation in hippocampal CA1 neurons 10 days after the first seeding, demonstrated by AT8 staining in hippocampal slices while absent in non-seeded hippocampal Tau slices or in seeded and non-seeded hippocampal slices derived from non-transgenic mice [Fig. 2a]. Basal synaptic excitability as well as synaptic plasticity were measured in hippocampal CA1 region following stimulation of Schaffer collaterals. This revealed impaired population spikes, after 10 days of seed induced Tau aggregation in Tau hippocampal slices. No significant changes in basal synaptic excitability were detected in wild-type hippocampal slices 10 days after Tau-seeding, nor in Tau-expressing hippocampal slices at 2 or 4 days after seeding [Fig. 2b]. This indicates that sufficient induction of Tau-aggregation is required to induce synaptic dysfunction. Furthermore, long-term potentiation of population spikes amplitude induced by tetanic stimulation of Schaffer collaterals revealed impaired synaptic plasticity in Tau-seeded compared to non-seeded Tau hippocampal slices [Fig. 2b]. Our data indicate significantly impaired synaptic plasticity and basal synaptic function by Tau-seed induced Tau-aggregation.

**Tau aggregation following seeding with synthetic pre-aggregated Tau spreads to synaptically and functionally connected brain regions in TauP301S transgenic mice**

To extend our assay in vivo, Tau-seeds were injected in frontal cortex and hippocampus of TauP301S mice and analyzed for Tau-aggregation in vivo. TauP301S transgenic mice develop Tau hyperphosphorylation, robust Tau-pathology, astro- and microgliosis, hippocampal atrophy, subtle defects in synaptic plasticity and motoric deficits, followed by the development of a progressive neurodegenerative phenotype characterized by initial clasping, hindlimb paralysis, development of hunchback, followed by premature death [73]. In the colony bred in our lab, this phenotype
starts at around 10–11 months [35, 63]. Hence, TauP301S mice were used for the Tau-seeding assay at the age of 3 months and analyzed 6 months post-injection—or earlier—before robust Tau-pathology or phenotypic changes were detected in non-seeded TauP301S mice. After a single injection of Tau-seeds in frontal cortex and hippocampus, robust Tau-pathology was demonstrated while practically absent in control injected, non-seeded TauP301S mice (Fig. 3aI). Biochemical analysis demonstrated the presence of sarkosyl insoluble Tau-aggregates following Tau-seeding (Fig. 3aII). Pathological Tau-alterations—including the characteristic 68 kDa Tau—were revealed by immunoblotting of sarkosyl insoluble and soluble fractions with antitotal Tau (HT7) antibody, anti-Tau P-S202/T205 (AT8) antibody, anti-Tau P-T181 (AT270) antibody and anti-Tau P-T212/TS214 (AT100) antibody (not shown) and by the characteristic mobility shift between sarkosyl soluble and sarkosyl insoluble Tau (Fig. 3aIII). The presence of fully mature NFTs, containing fibrillary Tau, was further confirmed by Gallyas silver and ThioS staining (Fig. 3aI).

To mimic the spreading pattern of Tau-pathology as observed in AD, we injected Tau-seeds in entorhinal cortex (EC) (Figs. 3b, 4b). Tau pathology was initially restricted to EC at 1.5 months post-injection, while gradually extending to functionally connected brain regions over time (Fig. 3bI). From 3.5 months post-injection onwards Tau pathology had spread to hippocampus, amygdala and cortical regions remote from the injection site (Fig. 3bI). NFTs were detected in EC, subiculum, hippocampal formation, amygdala, thalamus and frontal cortex (Fig. 3bI). Furthermore, Tau aggregation was also progressively induced in the contralateral hemisphere (Fig. 3bII, IV). Biochemical analysis of Tau-pathology confirmed the presence of aggregated Tau remote from the injection site, following dissection of ipsilateral frontal cortex of TauP301S mice 6 months post-injection in EC (Fig. 3bIII). This was also reflected in the characteristic shift in mobility in SDS PAGE of Tau in total brain extracts and increased ratio of sarkosyl insoluble to sarkosyl soluble Tau, with a pronounced presence of the 68 kDa band in the sarkosyl insoluble Tau fraction compared to non-injected mice. Noteworthy, injection of Tau-seeds in EC of non-transgenic mice did not induce Tau-pathology, detectable by AT8 staining analyzed 3.5 and 12 months post-injection (Fig. S4).

We next initiated Tau-pathology in basal ganglia, a brain region involved in different functions including motor control, as reflected in its dysfunction in Parkinson’s disease and Parkinsonism. From 3.5 months onwards and at 6 months post-injection of Tau-seeds in basal ganglia (in substantia nigra) Tau aggregation was detected in striatum, thalamus, brain stem and cortical regions including the motor cortex (Fig. 4c). To assess patterns of spreading of Tau-pathology semi-quantitatively we generated averaged heat maps of AT8-stained Tau-pathology in different mice, 6 months post-injection (n ≥ 3 for each condition) (Fig. 5). Our standardized AT8 staining protocol to stain forms of Tau, correlating strongly with Gallyas silver and ThioS staining (Fig. 4e) in brains was used [63]. The respective heat maps demonstrated that the spreading pattern of Tau-pathology at 6 months post-injection is dependent on the site of initiation and occurs along functionally connected brain circuits. However, it must be considered that some regions with a more scattered induction of Tau pathology including striatum and thalamus may be underrepresented in the heat maps. This is due to technical issues, because scattered NFTs are more easily leveled out compared to densely packed neuronal layers in the averaging process (Fig. 5).

Taken together, our results indicate that depending on the initial site of injection of Tau-seeds, i.e. cortical/hippocampal, basal ganglia or entorhinal cortex (Fig. 4a–d), different spreading patterns of Tau-pathology to functionally—and often symptomatically—connected brain regions was observed (Fig. 5). Spreading of Tau-pathology occurred by connectivity rather than proximity, raising the question and allowing us to analyze whether neuronal network function is affected by this process.

**Tau-pathology induced by Tau-seeding impairs synaptic function in hippocampal CA1 region and cognition in TauP301S mice**

Disease-specific patterns of glucose metabolism are generally considered to reflect neuronal dysfunction and have been demonstrated to correlate with high NFT load in different Tauopathies. To analyze the functional repercussions of spreading of Tau-aggregation through neuronal networks dependent on the site of initiation, we used in first instance FDG-PET. Mice injected with Tau-seeds and control mice were subjected to small-animal FDG-PET at 6 months post-injection. However, no significant differences were detected between Tau-seeded and non-seeded mice, despite the presence of robust Tau-pathology (Fig. 6a). This lack of changes should be ascribed to a lack of neurodegenerative processes induced by Tau-seeded Tau-aggregation, to the fact that neuronal dysfunction precedes significant changes in FDG-PET, or to the fact that changes in FDG-PET measured glucose metabolism were too small to detect with the current technique. Although, this technique was used successfully to reveal differences in glucose metabolism following contextual fear conditioning in rodents, and in different AD models [43, 46]. To gain further insight, we analyzed synaptic and cognitive function following Tau-seed induced Tau-aggregation. We assessed whether induction of Tau-aggregation through functional connections by Tau-seeding in EC, affected synaptic function in...
Fig. 5 Averaged heat maps for semi-quantitative analysis of spreading of Tau-pathology according to connectivity rather than proximity and along disease relevant patterns. Heat maps representing color scored averaged images of AT8 staining were generated for different injection paradigms. Heat maps of Tau mice, of Tau mice injected with vehicle, Tau mice injected with Tau-seeds in frontal cortex and hippocampus (FrCx/HC), Tau mice injected with Tau-seeds in substantia nigra (SN) and Tau mice injected with Tau-seeds in entorhinal cortex (EC), generated using Image J are presented. For Tau mice injected in EC, 2 different sagittal sections are presented situated closely to the medial longitudinal fissure and lateral. Schematic illustrations of the injection site and the section used for analysis are presented in the first column (modified after The GENSAT Project, website: http://www.gensat.org). Arrows indicate the injection site. Representative AT8 stainings (middle column) used for semi-quantitative analysis are presented for each condition, 6 months post-injection of Tau-seeds (scale bar 2000 µm). This reveals distinct patterns of Tau-pathology, encompassing brain regions with densely packed Tau-pathology, brain regions with scarcer Tau-pathology and unaffected brain regions. Heat maps were generated for semi-quantitative analysis of Tau-pathology (right column) by averaging AT8 stainings of multiple mice for each injection paradigm using Image J (n ≥ 3 for each condition). This demonstrates distinct patterns depending on the injection site, along functionally connected brain regions.
hippocampal neurons of CA1 following stimulation of the Schaffer collaterals 6 months post-seeding. Analysis of synaptic plasticity demonstrated a defect in LTP following Tau-aggregation in hippocampal CA1 neurons after induction of Tau-seeding in EC, while basal synaptic transmission was not affected in hippocampal CA1 neurons (Fig. 6b).

Synaptic fatigue and paired pulse ratio—generally considered parameters of presynaptic function—were not affected by Tau-seeding, suggesting a postsynaptic rather than presynaptic deficit (Fig. S3). In line with this, immunohistochemical staining with the presynaptic marker SV2 revealed no alterations following Tau-seeding in entorhinal cortex.
(results not shown). Long-term potentiation is generally believed to present a cellular model of learning and memory formation, and is induced during learning in CA1 [71]. Therefore, we assessed hippocampus-dependent cognitive function following Tau-seed induced Tau-aggregation. We first measured cognitive function after unilateral injection of Tau-seeds in Tau-transgenic mice, revealing no significant changes between unilateral Tau-seeded mice and non-seeded mice (results not shown). We next assessed cognitive function, 6 months following bilateral injections. This revealed a significant deficit in object recognition memory 1 h post-training in Tau-seeded mice compared to non-seeded mice (Fig. 6b). Our data thereby demonstrate that Tau-seeded Tau-aggregation is associated with impaired cognition in Tau-transgenic mice.

**Spreading of Tau aggregation along neuronal circuitries and impairment of associated behavioral outcomes is determined by the site of initial seeding in TauP301S mice**

We next analyzed whether the site of initiation of Tau-aggregation determines the specific behavioral outcomes. We measured motoric performance 6 months after initiation of Tau pathology in basal ganglia and EC, respectively. Quantitative scoring of hindlimb clasping revealed significantly increased clasping following initiation of Tau-pathology in basal ganglia, compared to initiation of Tau-pathology in EC, which did not induce significant clasping (Fig. 6c). Furthermore, we measured inverted grid hanging performance, to assess motor coordination and grip strength. Performance in inverted grid hanging was severely impaired 6 months post-initiation of Tau-aggregation by Tau-seeding in basal ganglia, while not significantly affected 6 months post-seeding in EC (Fig. 6c). Intracerebral injections of buffer only in basal ganglia did not induce Tau-aggregation and did not affect clasping or inverted grid hanging (Fig. 6c). Taken together, our data indicate that prion-like seeding of Tau-aggregation along synaptic connections affects selective functional brain circuitries, thereby determining the behavioral dysfunction depending on the site of initiation of Tau-pathology.

**“Early” pathological forms of Tau rather than fully mature NFTs as causal culprits for neuronal dysfunction**

To gain insight in potential forms of Tau responsible for the neuronal network dysfunction observed in our models, we performed biochemical and immunological analyses. We first assessed the induction of pathological Tau-forms in brains in vivo following Tau-seeding. Immunohistological analysis demonstrated the presence of misfolded Tau (MC1) and Tau hyperphosphorylated at pathological epitopes S202/T205 (AT8) and T212/S214 (AT100) (Fig. 7a). The presence of fully mature NFTs was further confirmed by Gallyas silver staining and ThioS staining (Figs. 3aI, 4e). Finally, electron microscopy (EM) analysis confirmed the clear presence of Tau fibrils and aggregated Tau (Fig. S5). Dot blot analysis with T22 antibody [40], demonstrated accumulation of Tau-oligomers in total homogenates following Tau-seeding (Fig. 7b). Tau-multimers were further analyzed in total homogenates in non-denaturing and non-reducing conditions in native PAGE. Larger Tau-aggregates, i.e. granular Tau (~40 Tau-molecules, 2.4 MDa) and fibrillary Tau, cannot enter the gel under these conditions. AT8 positive Tau-multimers were increased in brains following Tau-seeding (Fig. S6).

To gain more insight in early pathological forms of Tau, we performed a more detailed immunohistological analysis using AT8 staining. This demonstrated the presence of clearcut NFTs, which we previously demonstrated to correlate with Silver staining and ThioS staining in brains, but using more sensitive settings also different forms of AT8-stained Tau were revealed. More particularly, neurons with different stages of Tau-pathology ranging from early to fully mature NFTs were observed. In addition, diffuse and punctate staining patterns were observed in broader regions than regions displaying mature NFTs (Fig. 7c). This diffuse and punctate staining was markedly induced by Tau-seeding (Fig. S7) and observed in cell bodies but also very prominently in neuritic extensions of neurons. Taken together, Tau-seeding propagated diverse pathological Tau forms ranging from clearcut mature NFTs (somatic fibrillar Tau-aggregates) to “early” pathological forms of Tau, encompassing more diffuse and punctate AT8, as well as hyperphosphorylated, misfolded (MC1) and oligomeric Tau forms (stained with T22 or AT8).

We next analyzed the presence of these different forms of Tau following Tau-seed induced Tau-aggregation in primary neurons (PNC) and organotypic cultures (OC) (Fig. 7). Tau-seeding induced more robust and more abundant AT8 staining in organotypic hippocampal slices than in primary neurons, due to higher concentrations of Tau-seeds and topical application of the seeds on the slice. In primary neurons Tau-seed induced Tau-aggregation was less robust than previously published [27] since lower concentrations of Tau-seeds were used. Immunological analysis revealed the presence of pathological forms of Tau reflected by AT8, AT100 and MC1 positive signals in both models, OC and PNC (Fig. 7a). EM analysis revealed the presence of Tau fibrils in OC following Tau seeding, albeit less abundant than in brains (Fig. S5). Fibrils were not detected by EM analysis in primary neurons, paralleled by the lack of ThioS staining in PNC (results not shown). This indicates that fully mature Tau-fibrils were absent or present in very
different pathological forms of Tau are generated by Tau-seed induced Tau-aggregation. a Immunostaining of pathological forms of Tau reveals the presence of hyperphosphorylated Tau forms phosphorylated at Ser202/Thr205 (AT8) and T212/S214 (AT100), as well as misfolded Tau (MC1) antibody in all models, i.e. HEK293, brains, organotypic cultures and primary neurons, following Tau-seeding (scale bar ×20—200 µm, ×40—100 µm). b Tau-seeding increased Tau-oligomer concentrations assessed by dot blotting analysis with the Tau-oligomer specific T22 antibody on total homogenates. Quantitative analysis demonstrated accumulation of oligomeric Tau forms following Tau-seeding in brains ([n = 4; n = 4], (non-seeded; Tau-seeded)), organotypic cultures (OC) ([n = 5; n = 5] and primary neurons (PNC) ([n = 6; n = 5]) (mean ± SEM are presented; *p value <0.05). Dilution curves of samples of the different models are presented. c Immunohisto/cytological analysis with AT8 reveals different forms of AT8 stained Tau. In addition to mature and immature NFTs, diffuse and punctated staining are prominently observed by AT8-staining in organotypic hippocampal cultures and brains following Tau-seeding (left panels provide an overview picture and details of different types of AT8 staining observed in Tau-seeded OC and brains). In PNC, AT8 staining following standard fixation in 4 % PAF, demonstrates strong diffuse and punctated AT8 staining present throughout the culture dish in PNC, and robustly induced following Tau-seeding in TauP301S expressing PNC. Lower panels show AT8 staining (standard fixation) in non-seeded primary neurons derived from TauP301S mice (Tau) or non-transgenic mice (WT) (scale bar ×20—200 µm, ×40—100 µm)

Discussion

Accumulating evidence has demonstrated that Tau displays prion-like properties and that prion-like spreading of Tau-pathology occurs through connectivity rather than proximity [1]. This process has been proposed to underlie the stereotyped progression along unique brain circuitries of Tau-pathology and symptoms in Tauopathies [22, 28, 50, 53, 58, 74]. In this work, we demonstrated—for the first time—that templated Tau-misfolding induced by Tau-seeds through functionally connected neuro-anatomical pathways, impairs neuronal network function and associated behavioral outcomes, dependent on the initial site of seeding. More precisely, we demonstrated that small amounts of pre-aggregated synthetic Tau fragments, focally injected, without changing expression-level of Tau but only inducing Tau-misfolding, are sufficient to propagate Tau aggregation and impair neuronal network function and behavioral outcomes 6 months post-injection, dependent on the initial site of injection. These findings emphasize the potential relevance of this intensively studied process in the stereotypic progression of symptoms in Tauopathies. We have further extended our analysis to highlight early pathological forms of Tau, rather than fully mature NFT, correlate with the neuronal dysfunction induced by Tau-seeded Tau-misfolding.

We demonstrated that templated Tau-misfolding by Tau-seeds affected neuronal network activity in primary neuronal cultures. Primary cortical neurons display synchronized calcium oscillations in culture, which were previously shown to be modulated by PTX, a GABA_A receptor antagonist [44]. Exposure of cortical neurons to PTX renders calcium transients to exhibit increased amplitude, more regular frequency and higher synchronicity [44]. A refractory period has previously been identified which may play a role in increased synchronization. Our data indicate a significant dysregulation of spontaneous and PTX-induced calcium oscillations, indicating that Tau-seeded Tau-misfolding affects neuronal network activity. Our findings suggest that Tau-seeding impairs GABA-ergic synaptic transmission, based on the similarity of the effect of PTX and Tau-seeds on spontaneous oscillations. As we
further demonstrated that PTX elicted calcium transients are NMDA- and AMPA-dependent as shown previously [44], their reduced amplitudes in Tau-seeded neuronal cultures indicate impaired glutamergic, NMDA- and AMPA-dependent signaling. We further extended our analysis in models with conserved network architecture, i.e. to organotypic hippocampal slices [21]. In organotypic cultures, we demonstrated impaired population spike amplitude measured in hippocampal CA1 region following stimulation of Schaffer collaterals. This basal synaptic transmission is predominantly generated by excitatory glutameric (NMDA/AMPA-mediated) neurotransmission, further corroborating data obtained in primary neuronal cultures. Furthermore, measurement of LTP revealed that synaptic plasticity is impaired in organotypic slices by Tau-seed induced Tau misfolding. Notably, NMDA- and AMPA-receptor functions are critically involved in hippocampal LTP in CA1. Our data were further corroborated in vivo. Electrophysiological analysis in acute hippocampal slices revealed that LTP was affected 6 months post-induction of Tau-pathology by Tau-seeding in vivo, although basic synaptic transmission was not. The latter may be explained by the fact that effects of Tau-aggregation can be more easily compensated in vivo than in vitro, or that the aggregation process occurred more rapidly in vitro, or that organotypic cultures are more sensitive than the intact hippocampus in vivo. It must be noted that electrophysiological analysis in acute hippocampal slices was performed in hippocampal CA1 region, while initial Tau-seeding was performed in entorhinal cortex, indicating that neuronal function remote from the initial seeding site was affected. We further demonstrated conserved presynaptic parameters including paired pulse ratio, synaptic fatigue and SV2 staining, pointing towards a postsynaptic mechanism. Together with the results obtained in primary neurons, indicating impaired NMDA/AMPA-dependent neuronal network function following Tau-seeding, our data are in line with a role of pathological Tau forms in postsynaptic dysfunction, including NMDA/AMPA dysfunction as previously shown [8, 60, 70]. We further assessed behavioral effects, and demonstrated that cognition, measured in an object recognition task was impaired in bilaterally injected mice, 6 months post-injection. Together our data indicate that Tau-seed induced misfolding of Tau, leading to Tau-aggregation through connectivity, affects neuronal function, neuronal network activity and behavioral outcome, and hence could contribute to progression of the symptoms in Tauopathies.

Prion-like induction of Tau-pathology—a process which raised considerable scientific interest—has been elegantly demonstrated and analyzed in exquisite detail for different aspects [1, 12–14, 19, 20, 22, 26, 28, 32, 35, 37, 40, 53, 72]. The functional repercussions of this process remained however, to be analyzed. This question is important to evaluate its relevance in the pathogenetic process of Tauopathies. In AD, Tau-pathology is known to progress according to stereotypical and predictable patterns reflected in its incorporation in criteria for the neuropathological diagnosis of AD [6, 34]. The first neurons to be affected are in entorhinal cortex (EC) (stage I), the neurons that give rise to the perforant pathway, the major projection connecting cerebral cortex with the hippocampus [23, 33]. Next NFTs spread to the CA1 region of the hippocampus and accumulate in limbic structures such as the subiculum (stage II–III) and the amygdala, thalamus, and claustrum (stage IV). Finally, NFTs spread to isocortical areas (stage V–VI). Symptoms in AD are strongly correlated with this characteristic appearance of NFTs. In this work, we mimic spreading of Tau-pathology following seeding in entorhinal cortex of TauP301S mice, similar as observed in AD. Tau pathology starts first in the entorhinal cortex, subsequently in CA1, the subiculum and CA3-4 and later in the DG, and finally in neocortical areas (stages V and IV), according to the Braak and Braak stages. Noteworthy, minor discrepancy between spreading of Tau-pathology in AD [EC, subsequently CA1/subiculum/CA3-4 and later dentate gyrus (DG)] and functional connectivity (EC, subsequently DG/CA3-4 and then CA1/subiculum) may be ascribed to additional factors determining selective vulnerability or protection in these regions, which appear to be recapitulated in our model, as the AD pattern was mimicked following seeding in EC. It must be noted however that in contrast to AD and sporadic Tauopathies, characterized by aggregation of wild type Tau, we used in the current work recipient Tau and inducer Tau-seeds mutated at Proline 301, as this combination results in the highest Tau-aggregation efficiency. Previous work also indicated that mutation of Proline 301, rather than its substitution by Serine or Leucine, is determining aggregation efficiency [27]. However, wild type Tau acting as recipient, in combination with either wild-type or mutant Tau seeds as inducer has been demonstrated to be capable of prion-like Tau seeding, albeit much less efficient. The potential of wild type Tau to undergo prion-like Tau seeding allows a (cautious) extrapolation of our data in the context of AD or sporadic Tauopathies, characterized by aggregation of wild type Tau. Hence, neuronal network dysfunction and associated behavioral dysfunctions induced by prion-like seeding and spreading of Tau-pathology along functionally connected circuitries could relate to symptomatic progression in AD and related Tauopathies.

Besides in AD patients, spreading of Tau-aggregation according to a characteristic pattern along functionally connected brain circuitries is also observed in argyrophilic grain disease, a different Tauopathy. Other Tauopathies are very heterogeneous between individuals with identical mutations, including for patients with Tau mutated at Proline 301 (P301L) [4]. This heterogeneity hampers
forms of Tau or “pre-tangle stage” pathological forms of Tau, are responsible for neuronal network dysfunction. This is further supported by their abundant induction in brains and in organotypic cultures following Tau-seeding. Taken together our data suggest that early pathological forms of Tau rather than fully mature NFTs may represent the causal culprits. Final proof can only be delivered by selective elimination of different pathological forms of Tau and analysis of the functional repercussions. Our observations fit however with previous observations using elegant approaches to determine the repercussions of Tau-pathology, and more particularly of NFTs on neuronal function in vivo [18, 30, 38, 48, 52, 54, 61, 65, 66, 69]. This demonstrated either no effects of NFTs in neurons on calcium or Arc responses [38, 52]. Furthermore, using inducible expression of Tau or pro-aggregant Tau, reversibility of synaptic deficits despite the continued presence of NFTs was demonstrated, indicating association of synaptic defects with the aggregation process and early pathological Tau forms, rather than with the full-blown NFTs [3, 30, 54, 61, 65, 66, 69]. These data are in line with clear demonstration of detrimental effects of Tau-oligomers on neuronal function and behavior, as demonstrated following acute injection of oligomeric Tau and immunization with anti-Tau oligomeric antibodies [10, 11, 39, 40]. Our findings are furthermore in line with previous reports demonstrating that Tau overexpression or Tau-alterations affect neuronal function or function of connected neurons [29, 31, 42, 47, 48, 56, 57, 63, 73]. It must be noted that in the current work, Tau-expression is not affected, but only misfolding of Tau is induced by templated seeding by focal administration of small amounts of seeds. We demonstrate that this templated Tau-misfolding is sufficient to propagate neuronal network dysfunction and behavioral outcomes, which correlate with the presence of early pathological forms of Tau, including Tau oligomers, rather than with the presence of fully mature Tau fibrils.

In summary, our data indicate for the first time and unequivocally, using in vitro, ex vivo and in vivo approaches that (i) prion-like Tau-seed induced Tau-aggregation with NFT formation—a mechanism under intensive investigation—causes synaptic and neuronal network dysfunction, resulting in behavioral impairments. Our data thereby indicate that prion-like spreading of Tau-pathology may contribute to progression of disease symptoms in Tauopathies by affecting intrinsic functional critical networks. Furthermore, our data indicate unequivocally that (ii) behavioral outcomes following seeding in Tau P301 transgenic mice, are determined by the initial site of Tau seeding. Hence, motoric problems were demonstrated following Tau-seeding in basal ganglia (substantia nigra), while absent following injection in entorhinal cortex, resulting in cognitive defects. These findings are reminiscent of the heterogeneity of clinical symptoms in familial cases with P301 mutations,
in which initial seed formation by environmental, genetic or accidental factors, may determine the behavioral outcomes. Finally, (iii) our results support a role of early pathological forms of Tau, including oligomeric Tau rather than fully mature NFTs as pathogenic culprits of prion-like induced spreading of neuronal dysfunction. Our findings provide a basis to further identify the molecular mechanisms involved in Tau-seed induced synaptic dysfunction and provide a model to develop novel therapeutic strategies targeting Tau-seed induced neuronal dysfunction, and to analyze repercussions on neuronal function induced by different Tau-“strains”.

Acknowledgments This work was supported by the Belgian Fonds National pour la Recherche Scientifique—Fonds de la Recherche Scientifique (FNRS-FRS; Qualified Researcher, Impulse Financing, Research Credits), by Interuniversity Attraction Poles Programme-Belgian State-Belgian Science Policy, The Belgian Fonds de la Recherche Scientifique Médicale, by the Institute for the Promotion of Innovation by Science and Technology (IWT) in Flanders (IWT O&O), Belgium.

Conflict of interest The authors have no competing interest. E.P., O&O), Belgium.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Ahmed Z, Cooper J, Murray TK, Gam K, McNaughton E, Clarke H, Farhizaker S, Ward MA, Cavallini A, Jackson S, Bose S, Clavaguera F, Tolnay M, Lavenir I, Goedert M, Hutton ML, O’Neill MJ (2014) A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol 127:667–683

2. Arnold SE, Toledo JB, Appleby DH, Xie SX, Wang LS, Baek Y, Wolk DA, Lee EB, Miller BL, Lee VM, Trojanowski JQ (2013) Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. J Comp Neurol 521:4339–4355

3. Berger Z, Roden H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K, Knight J, Dickson D, Andorfer C, Rosenberry TL, Lewis J, Hutton M, Janus C (2007) Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 27(14):3650–3662

4. Bird TD, Ncholin D, Poorkaj P, Cherrier M, Kaye J, Payami H, Peskind E, Lampe TH, Nemens E, Boyer PJ, Schellenberg GD (1999) A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L). Brain 122:741–756

5. Boluda S, Iba M, Zhang B, Raible KM, Lee VM, Trojanowski JQ (2015) Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer’s disease or corticobasal degeneration brains. Acta Neuropathol 129(2):221–237

6. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82:239–259

7. Brion JP, Flament-Durand J,ustin P (1986) Alzheimer’s disease and tau proteins. Lancet 2:1098

8. Burnouf S, Martire A, Desirbourg M, Laurent C, Belarbi K, Leboucher A, Fernandez-Gomez FJ, Troquier L, Eddarkaoui S, Grosjean ME, Demeyer D, Muhr-Tailleux A, Buisson A, Sergeant N, Hamdane M, Humez S, Popoli P, Buée L, Blum D (2013) NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model. Aging Cell 12:11–23

9. Casteels C, Vunckx K, Aelvoet SA, Bormans G, Van Laere K, Koole M (2013) Construction and evaluation of quantitative small-animal PET probabilistic atlases for [18F] FDG and [18F]FECT functional mapping of the mouse brain. PLoS One 8:e65286

10. Castillo-Carranza DL, Gerson JE, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA, Kayed R (2014) Specific targeting of Tau oligomers in Htau mice prevents cognitive impairment and Tau toxicity following injection with brain-derived Tau oligomeric seeds. J Alzheimers Dis 40:S97–S111

11. Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, Estes DM, Barrett ADT, Dineley KT, Jackson GR, Kayed R (2014) Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci 34:4260–4272

12. Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, Probst A, Winkler DT, Reichwald J, Staufenbiel M, Ghetti B, Goedert M, Tolnay M (2013) Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci USA 110:9535–9540

13. Clavaguera F, Belmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11:909–913

14. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT (2012) Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron 73:685–697

15. Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Verheyen P, De Deyn PP, Robert C, Chabriat H, Van den Haute C, Prick K, Uitti RJ, Jellinger K, Serrano-Paredes C, Seppa¨ nen L, Sirveen M, Thiru E, Moechars D, Memmert D, Goedert M, Jucker M, Suuronen T, Van LF (2009) Neuronal and axonal defects of amyloid precursor [V717I] transgenic mice. J Neurosci 34:6212–6222

16. Dewachter I, Reverse D, Caluwaerts N, Sengupta U, Goedert M, Tolnay M (2007) Accumulation of pathological forms of tau in the hippocampus of “young” PS19 tau transgenic mice following intracerebral injection with brain-derived Tau oligomeric seeds. Acta Neuropathol 129:875–894
19. Frost B, Diamond MI (2010) Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 11:155–159

20. Frost B, Jacks RL, Diamond MI (2009) Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284:12845–12852

21. Gaubier BH, Capogna M, Debanne D, McKinney RA, Thompson SM (1997) Organotypic slice cultures: a technique has come of age. Trends Neurosci 20:471–477

22. Goedert M, Clavaguera F, Tolnay M (2010) The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci 33:317–325

23. Gomez-Isla T, Price JL, McKee J, Morris JC, Growdon JH, Hyman BT (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J Neurosci 16:4491–4500

24. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol 41:17–24

25. Guo JL, Coveil DJ, Daniels JP, Iba M, Stieber A, Zhang B, Riddle DM, Kwong LK, Xu Y, Trojanowski JQ, Lee VM (2013) Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell 154:103–117

26. Guo JL, Lee VM (2011) Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem 286:15317–15331

27. Guo JL, Lee VM (2013) Neurofibrillary tangle-like tau pathology induced by synthetic tau fibrils in primary neurons over-expressing mutant tau. FEBS Lett 587:717–723

28. Guo JL, Lee VM (2014) Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med 20:130–138

29. Heward C, Gougak D, Ando K, Leroy K, Suain V, Yilmaz Z, Guo JL, Lee VM (2014) Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med 20:130–138

30. Hochgrafe K, Sydow A, Mandelkow EM (2013) Regulatable proteases J Biol Chem 288:15317–15331

31. Hoffmann NA, Dorostkar MM, Blumenstock S, Goedert M, Herms J (2013) Impaired plasticity of cortical dendritic spines in P301S tau transgenic mice. Acta Neuropathol Commun 1:82

32. Holmes BB, DeVos SL, Kuchibhotla KV, Muzi-Falconi M, Brody EM, Marasa J, Bagchi DP, Kottubauer PT, Miller TM, Papy-Garcia D, Diamond MI (2013) Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci USA 110:E3138–E3147

33. Hyman BT, Kromer LJ, Van Hoesen GW (1987) Reinnervation of the hippocampal perforant pathway zone in Alzheimer’s disease. Am J Pathol 127:257–270

34. Hyman BT, Trojanowski JQ (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56:1095–1097

35. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM (2013) Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer’s-like tauopathy. J Neurosci 33:1024–1037

36. Jaworski T, Dewachter I, Lechat B, Gees M, Kremer A, Demedts D, Borghgraef P, Devijver H, Kugler S, Patel S, Woodgett JR, Van LF (2011) GSK-3alpha/beta kinases and amyloid production in vivo. Nature 480:E4–E5

37. Kfouri N, Holmes BB, Jiang H, Holtzman DM, Diamond MI (2012) Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem 287:19440–19451

38. Kuchibhotla KV, Wegmann S, Kopeikina KJ, Hawkes J, Rudinskas N, Andermann ML, Spires-Jones TL, Bacskai BJ, Hyman BT (2014) Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc Natl Acad Sci USA 111:510–514

39. Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Munoz MJ, Jackson GR, Kayed R (2010) Preparation and characterization of neurototoxic Tau oligomers. Biochemistry 49:10039–10041

40. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, Kayed R (2012) Identification of oligomers at early stages of tau aggregation in Alzheimer’s disease. FASEB J 26:1946–1959

41. Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121–1159

42. Leroy K, Bretteville A, Schindkowski D, Gilissen E, Authelet M, De DR, Veele R, Brion JP (2007) Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am J Pathol 171:976–992

43. Luyten L, Casteels C, Vansteenwegen D, van KK, Koole M, Van HK, Nuttin B (2012) Micro-postion emission tomography imaging of rat brain metabolism during expression of context-dependent conditioning. J Neurosci 32:254–263

44. Murphy TH, Blatter LA, Wier WG, Baraban JM (1992) Spontaneous synchronous synaptic calcium transients in cultured cortical neurons. J Neurosci 12:4834–4845

45. Paxinos G, Franklin KB (2001) The mouse brain in stereotaxic coordinates. Academic, San Diego

46. Poisnel G, Herrad AS, El Tannir ET, Bourrin E, Volk A, Kober F, Delatour B, Delzescaux T, Debeir T, Rooney T, Benavides J, Hantraye P, Dhennain M (2012) Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer’s disease. Neurobiol Aging 33:1995–2005

47. Polydoro M, Acker CM, Duff K, Castillo PE, Davies P (2009) Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tauopathy. J Neurosci 29:10741–10749

48. Polydoro M, Dhahla VL, Pooler AM, Nicholls SB, McKinney AP, Sanchez L, Pitstick R, Carlson GA, Staley KJ, Spires-Jones TL, Hyman BT (2014) Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer’s disease model. Acta Neuropathol 127:257–270

49. Postina R, Schroeder A, Dewachter I, Bohl J, Endres K, Hiemke C, Blessing M, Flamaz P, Dequenne A, Godaux E, Van LF, Fahrenholz F (2004) A disinhibitory network leads to presynaptic deficits in an early Alzheimer’s disease. FEBS Lett 587:717–723

50. Postina R, Schroeder A, Dewachter I, Bohl J, Endres K, Hiemke C, Blessing M, Flamez P, Dequenne A, Godaux E, Van LF, Fahrenholz F (2004) A disinhibitory network leads to presynaptic deficits in an early Alzheimer’s disease. FEBS Lett 587:717–723

51. Rampon C, Tang YP, Goodhouse J, Shimizu E, Kiny M, Tsien JZ (2014) Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem 287:19440–19451

52. Rudinskiy N, Hawkes JM, Wegmann S, Kuchibhotla KV, Muzi-Falconi M, Betensky RA, Spires-Jones TL, Hyman BT (2014) Tau pathology does not affect experience-driven single-neuron and network-wide Arc/Arg3.1 responses. Acta Neuropathol Commun 2:63

53. Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, Barker SJ, Foley AC, Thorpe JR, Serpell LC, Miller TM, Grinberg LT, Seeley WW, Diamond MI (2014) Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82:1271–1288
54. SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, deTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH (2005) Tau suppression in a neurodegenerative mouse model improves memory function. J Neurosci 29:4708–4718

55. Santos SF, Pierrot N, Morel N, Gailly P, Sindic C, Octave JN (2009) Expression of human amyloid precursor protein in rat cortical neurons inhibits calcium oscillations. J Neurosci 29:4708–4718

56. Saul A, Sprenger F, Bayer TA, Wirths O (2013) Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer’s disease. Neurobiol Aging 34:2564–2573

57. Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, Buee L (2006) Alzheimer’s disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 169:599–616

58. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD (2009) Neurodegenerative diseases target large-scale human brain networks. Neuron 62:42–52

59. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1:a006189

60. Shao C, Mirra S, Sait H, Sacktor T, Sigurdsson E (2011) Post-synaptic degeneration as revealed by PSD-95 reduction occurs after advanced Aβ and tau pathology in transgenic mouse models of Alzheimer’s disease. Acta Neuropathol 122:285–292

61. Spires TL, Orne JD, SantaCruz K, Pitstick R, Carlson GA, Ashe KH, Hyman BT (2006) Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol 168:1598–1607

62. Spires-Jones TL, Stoothoff WH, de CA, Jones PB, Hyman BT (2009) Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci 32:150–159

63. Stancu IC, Ris L, Vasconcelos B, Marinangeli C, Goeminne L, Laporte V, Haylani LE, Couturier J, Schakman O, Gailly P, Pierrot N, Kienlen-Campard P, Octave JN, Dewachter I (2014) Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer’s disease. FASEB J 28:2620–2631

64. Stoppini L, Buchs PA, Muller D (1991) A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 37:173–182

65. Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, Drexler D, Zhou L, Rune G, Mandelkow E, D’Hooge R, Alzheimer C, Mandelkow EM (2011) Reversibility of Tau-related cognitive defects in a regulatable FTD mouse model. J Mol Neurosci 45:432–437

66. Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, Drexler D, Zhou L, Rune G, Mandelkow E, D’Hooge R, Alzheimer C, Mandelkow EM (2011) Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J Neurosci 31:2511–2525

67. Terwel D, Lasrado R, Snaauwaert J, Vandeweerdt E, Van Haesendonck C, Borghgraef P, Van Leuven F (2005) Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J Biol Chem 280(5):3963–3973

68. Terwel D, Muylaelaert D, Dewachter I, Borghgraef P, Croes S, Devijver H, Van Leuven F (2008) Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am J Pathol 172(3):786–798

69. Van der Jeugd A, Hochgrafe K, Ahmed T, Decker JM, Sydow A, Hofmann A, Wu D, Messing L, Balschun D, D’Hooge R, Mandelkow EM (2012) Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau. Acta Neuropathol 123:787–805

70. Warmus BA, Sekar DR, McCutchen E, Schellenberg GD, Roberts RC, McMahon LL, Roberson ED (2014) Tau-mediated NMDA receptor impairment underlies dysfunction of a selectively vulnerable network in a mouse model of Frontotemporal Dementia. J Neurosci 34:16482–16495

71. Whitlock JR, Heynen AJ, Shuler MG, Bear MF (2006) Learning induces long-term potentiation in the hippocampus. Science 313:1093–1097

72. Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM (2013) Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80:402–414

73. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53:337–351

74. Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW (2012) Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron 73:1216–1227